Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry.

ABSTRACT:

Background and aims

Peripartum cardiomyopathy (PPCM) remains a serious threat to maternal health around the world. While bromocriptine, in addition to standard treatment for heart failure, presents a promising pathophysiology-based disease-specific treatment option in PPCM, the evidence regarding its efficacy remains limited. This study aimed to determine whether bromocriptine treatment is associated with improved maternal outcomes in PPCM.

Methods

Peripartum cardiomyopathy patients from the EORP PPCM registry with available follow-up were included. The main exposure of this exploratory non-randomized analysis was bromocriptine treatment, and the main outcome was a composite endpoint of maternal outcome [death or hospital readmission within the first 6 months after diagnosis

SUBMITTER: van der Meer P 

PROVIDER: S-EPMC11905762 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature